C2N Diagnostics Says FDA's Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer's Disease Pathology [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Food and Drug Administration to approve donanemab for treatment of early Alzheimer's disease. Researchers used C2N's Precivity-p-tau217 blood biomarker in its Phase 3 clinical trial and analysis for donanemab , which was highlighted in the article "Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial " in the Journal of the American Medical Association. Eli Lilly and Company says donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease. Exploratory outcomes included changes in plasma p-tau217 at 76 weeks and other time-based analyses. Lilly stresses that donanemab is not a cure for Alzheimer's disease, but it has been shown to slow disease progression in clinical trials. C2N believes it is uniquely positioned to support the medical community in confirming Alzheimer's disease pathology with its Precivity™ portfolio of tests. The PrecivityAD2™ blood test is a clinical care assay
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $1,023.00 price target on the stock.MarketBeat
- Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio [Yahoo! Finance]Yahoo! Finance
- Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation [Yahoo! Finance]Yahoo! Finance
- Forget Eli Lilly: 3 Biotech Stocks to Buy Instead [Yahoo! Finance]Yahoo! Finance
- Ozempic linked to rare cases of vision loss in Harvard study [Fortune]Fortune
LLY
Earnings
- 4/30/24 - Beat
LLY
Sec Filings
- 7/3/24 - Form 4
- 7/2/24 - Form 4
- 7/1/24 - Form 4
- LLY's page on the SEC website